• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ky­owa Kirin bol­sters cam­paign to close racial dis­par­i­ty gap in rare ‘lym­phoma of the skin’

3 years ago
Pharma
Marketing

Form 483 re­veals spore con­t­a­m­i­na­tion at a South Ko­re­an man­u­fac­tur­ing site last year

3 years ago
Pharma
FDA+

In­te­gral Mol­e­c­u­lar's off-tar­get pro­tein bind­ing ar­ray nabs first spot in FDA pi­lot to speed new drug de­vel­op­ment ...

3 years ago
R&D
FDA+

Eight years lat­er, FDA re­vis­es draft guid­ance on pe­di­atric clin­i­cal phar­ma­col­o­gy stud­ies

3 years ago
FDA+

In­vestor suit fu­eled by news ar­ti­cles over failed can­cer drug ends in $24M set­tle­ment

3 years ago
Deals
Law

Io­n­is, As­traZeneca go­ing to FDA with PhI­II da­ta in hand; Glaukos touts dou­ble PhI­II win in eye im­plant

3 years ago
News Briefing

Paci­ra looks to ex­pand use of Ex­par­el for pain re­lief fol­low­ing knee re­place­ment surgery

3 years ago
R&D

Shoot­ing for a heav­i­ly pre-treat­ed niche can­cer mar­ket, Bi­cy­cle re­veals a 'mixed' da­ta cut

3 years ago
R&D

'Con­flicts of in­ter­est': SEC charges Per­cep­tive Ad­vi­sors over SPAC deal­ings, set­tles for $1.5M penal­ty

3 years ago
People
Law

Tiny tran­scrip­tome biotech se­cures Se­ries A to ramp up au­to­mat­ed R&D ef­forts in race to­ward clin­ic

3 years ago
Financing

Af­ter block­ing Grail ac­qui­si­tion, EU leaves Il­lu­mi­na with few good op­tions

3 years ago
Deals
Diagnostics

Fol­low­ing luke­warm launch and lay­offs, Zealand Phar­ma is li­cens­ing out its di­a­betes drug to No­vo Nordisk

3 years ago
Deals

Good Ther­a­peu­tics sells PD-1 IL-2 pro­gram to Roche for $250M and will march on with a sim­i­lar name, but in Latin

3 years ago
Deals
Pharma

Watch out Mod­er­na: John Maraganore, ARCH and Beam are hatch­ing a plat­form play 'to lead the fu­ture of RNA ther­a­pies'

3 years ago
Startups
Cell/Gene Tx

A Rich Hey­man biotech backed by a top Salk sci­en­tist is auc­tioned off for its dwin­dling cash re­serves

3 years ago
Deals

Over $50M in fed­er­al funds are go­ing to Vir­ginia’s phar­ma man­u­fac­tur­ing sec­tor

3 years ago
Financing
Pharma

'Vac­cines are not par­ti­san': White House ramps up de­liv­ery of bi­va­lent boost­ers

3 years ago
Coronavirus

Bay­er agrees to pay $40M to set­tle kick­back, safe­ty claims sparked by whistle­blow­er

3 years ago
Pharma
Law

Boehringer In­gel­heim preps FDA sub­mis­sion with new da­ta in rare pe­di­atric lung dis­ease

3 years ago
R&D
Pharma

Sun Phar­ma en­lists der­ma­tol­ogy HCPs to talk about per­son­al ac­ne ex­pe­ri­ences in new cam­paign

3 years ago
Pharma
Marketing

As­traZeneca ex­pands its block­buster Imfinzi fran­chise with new ap­proval in bil­iary tract can­cer

3 years ago
Pharma
FDA+

For­mer con­tract man­u­fac­tur­er CEO sen­tenced to prison for ship­ping con­t­a­m­i­nat­ed drugs to chil­dren's hos­pi­tals

3 years ago
Pharma
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er boosts sci­ence with pop cul­ture takes on Face­book; BMS, Jazz de­but new SU2C teams

3 years ago
Pharma
Marketing

Noth­ing to laugh about: What hap­pened to hu­mor in phar­ma ad­ver­tis­ing?

3 years ago
Pharma
Marketing
First page Previous page 461462463464465466467 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times